Notice: This company has been marked as potentially delisted and may not be actively trading. Positive News SentimentPositive NewsNASDAQ:INTS Intensity Therapeutics, Inc. Common stock (INTS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesOwnershipShort InterestTrends About Intensity Therapeutics, Inc. Common stock Stock (NASDAQ:INTS) 30 days 90 days 365 days Advanced Chart Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get INTS alerts:Sign Up Key Stats Today's Range$1.73▼$1.9950-Day Range N/A52-Week Range N/AVolume95,326 shsAverage Volume27,396 shsMarket Capitalization$26.08 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingBuy Company OverviewIntensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.Read More… Intensity Therapeutics, Inc. Common stock Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks60th Percentile Overall ScoreINTS MarketRank™: Intensity Therapeutics, Inc. Common stock scored higher than 60% of companies evaluated by MarketBeat, and ranked 543rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingIntensity Therapeutics, Inc. Common stock has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIntensity Therapeutics, Inc. Common stock has only been the subject of 1 research reports in the past 90 days.Read more about Intensity Therapeutics, Inc. Common stock's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intensity Therapeutics, Inc. Common stock are expected to grow in the coming year, from ($1.20) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intensity Therapeutics, Inc. Common stock is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intensity Therapeutics, Inc. Common stock is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntensity Therapeutics, Inc. Common stock has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.56% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics, Inc. Common stock has recently decreased by 10.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntensity Therapeutics, Inc. Common stock does not currently pay a dividend.Dividend GrowthIntensity Therapeutics, Inc. Common stock does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.56% of the float of Intensity Therapeutics, Inc. Common stock has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics, Inc. Common stock has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics, Inc. Common stock has recently decreased by 10.62%, indicating that investor sentiment is improving significantly. News and Social MediaN/ANews SentimentN/A Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Intensity Therapeutics, Inc. Common stock insiders have not sold or bought any company stock.Percentage Held by Insiders18.60% of the stock of Intensity Therapeutics, Inc. Common stock is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.74% of the stock of Intensity Therapeutics, Inc. Common stock is held by institutions.Read more about Intensity Therapeutics, Inc. Common stock's insider trading history. Receive INTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intensity Therapeutics, Inc. Common stock and its competitors with MarketBeat's FREE daily newsletter. Email Address INTS Stock News HeadlinesIntensity Therapeutics files to sell 1.24M shares of common stock for holdersDecember 14, 2024 | markets.businessinsider.comIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)December 12, 2024 | prnewswire.comThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… December 22, 2024 | ProsperityPub (Ad)Promising Clinical Progress and Financial Stability Drive Positive Outlook for Intensity Therapeutics, Inc.November 22, 2024 | markets.businessinsider.comIntensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private PlacementNovember 21, 2024 | prnewswire.comIntensity Therapeutics presents INT230-6 Phase 1/2 daya in SarcomaNovember 18, 2024 | markets.businessinsider.comIntensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)November 18, 2024 | prnewswire.comIntensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 16, 2024 | finanznachrichten.deSee More Headlines INTS Stock Analysis - Frequently Asked Questions How were Intensity Therapeutics, Inc. Common stock's earnings last quarter? Intensity Therapeutics, Inc. Common stock (NASDAQ:INTS) released its quarterly earnings results on Friday, August, 9th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.04. When did Intensity Therapeutics, Inc. Common stock IPO? Intensity Therapeutics, Inc. Common stock (INTS) raised $20 million in an IPO on Friday, June 30th 2023. The company issued 3,900,000 shares at $5.00 per share. Who are Intensity Therapeutics, Inc. Common stock's major shareholders? Top institutional shareholders of Intensity Therapeutics, Inc. Common stock include Geode Capital Management LLC (0.47%). What other stocks do shareholders of Intensity Therapeutics, Inc. Common stock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics, Inc. Common stock investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ). Company Calendar Last Earnings8/09/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INTS CUSIPN/A CIK1567264 Webwww.intensitytherapeutics.com Phone203 221 7381FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+352.1%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-209.73% Return on Assets-149.19% Debt Debt-to-Equity Ratio0.04 Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.96 per share Price / Book1.96Miscellaneous Outstanding Shares13,870,000Free Float11,289,000Market Cap$26.08 million OptionableNot Optionable Beta3.61 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:INTS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics, Inc. Common stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics, Inc. Common stock With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
